RxDoctor Payments Data

William Massengale, MD

Dermatology · Prairieville, LANPI 1952398893

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $181,686 of the $225,303 with a category attached, or 80.6%. 41 manufacturers reported payments, led by Galderma Laboratories, L.p. at 40.8% of the total. 2025 is the largest year on record at $145,997, more than ten times the $12,851 reported in 2019. Among dermatology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$225,303in general payments, 2019–2025

Across 1,161 payments — averaging $194.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$92K
  • AbbVie$57K
  • Lilly USA, LLC$50K
  • Johnson & Johnson$14K
  • Arcutis Biotherapeutics, Inc.$2K
  • Sanofi$2K
  • plus $8K from 35 others

What the payments were for

  • Consulting fees$10,4255%
  • Speaking & faculty fees$181,68681%
  • Travel & lodging$9,0404%
  • Food & beverage$23,61610%
  • Education$5360%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$225,303 in reported general payments places this provider in the 95th percentile of 189 dermatology providers in Louisiana.

See all dermatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$195,105
Medicare patients
603
Services billed
3,396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$233,843
OtezlaApremilast35$180,892
Taltz AutoinjectorIxekizumab21$142,080
Dupixent PenDupilumab28$126,052
Dupixent SyringeDupilumab13$49,251
Ivermectin68$18,635
Doxycycline Ir-DrDoxycycline Monohydrate11$8,850
Triamcinolone Acetonide318$4,129
Clobetasol Propionate120$3,066
Ketoconazole162$2,431
Tretinoin28$2,339
Tacrolimus19$2,268
Minoxidil209$1,582
ValacyclovirValacyclovir Hcl33$1,277
Fluconazole98$1,188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$198$180,89235 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 189 dermatology providers in Louisiana.

Other dermatology in Prairieville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →